Anna Mullard
4 Papers
Anna Mullard is an academic researcher. The author has contributed to research in topics: Internal medicine & Lung cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Janet E. Brown,Kara-Louise Royle,Walter M Gregory,Christy Ralph,Anthony Maraveyas,O.S. Din,Tim Eisen,Paul Nathan,Thomas Powles,Richard Griffiths,Robert Jones,Naveen S. Vasudev,Matthew Wheater,A. Hamid,T. Waddell,Rhona McMenemin,Poulam M. Patel,James Larkin,Guy Faust,Jayne Swain,Janine C Bestall,Christopher McCabe,David M. Meads,Vicky Goh,Tze Min Wah,Julia Brown,Jenny Hewison,Peter Selby,Fiona Collinson,Judith E. Carser,Gopalakrishnan Srinivasan,Fiona Thistlewaite,Ashraf Azzabi,Mark Beresford,David Farrugia,Marios P. Decatris,Carys Thomas,Joanna Gale,J. J. McAleer,A. Clayton,Ekaterini Boleti,T. Geldart,Santhanam Sundar,Jason F. Lester,Nachi Palaniappan,Mohan Hingorani,Khaliqur Rehman,Mohammad Emrul Hasan Khan,Naveed Sarwar,Janine Graham,Alastair M. Thomson,Narayanan Srihari,D. Sheehan,Rajaguru Srinivasan,O. Khan,Andrew Stockdale Jane Worlding,Stergios Boussios,N Stuart,Carey F MacDonald-Smith,F. Danwata,Duncan McLaren,Aravindhan Sundaramurthy,Anna Lydon,Sharon Beesley,Kathryn Lees,Mohini Varughese,Emma Gray,Angela Scott,Mark Baxter,Anna Mullard,Pasquale F. Innominato,Gaurav Kapur,Ashok Kumar,Natalie Charnley,C. Manetta,Prabir Chakraborti,Prantik Das,Sarah Rudman,H. Taylor,Christos Mikropoulos,Martin Highley,D Muthukumar,Anjali Zarkar,Roy Vergis,Seshadri Sriprasad,P. Brulinski,Amanda Clarke,R.D. Osbourne,Melanie Harvey,Renata Dega,G. Sparrow,Urmila Barthakur,E. Beaumont,Agnieszka Michael,Emilio Porfiri,Faisal Azam,Ravi Kodavtiganti +96 more
TL;DR: In this article , the authors compared a drug-free interval strategy with a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma (CRC) patients.
37
Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up
Alison Finall,Gareth Davies,Trevor Jones,Gwion Emlyn,P. Huey,Anna Mullard +5 more
TL;DR: Whether turnaround times for reporting epidermal growth factor receptors (EGFR) by next-generation sequencing (NGS) alone is sufficient to meet the needs of lung cancer patients is determined.
13
Digital Remote Monitoring Using an mHealth Solution for Survivors of Cancer: Protocol for a Pilot Observational Study
Pasquale F Innominato,Jamie H Macdonald,Wendy Saxton,Laura Longshaw,Rachel Granger,Iman Naja,Carlo Allocca,Ruth Edwards,Solah Rasheed,Frans Folkvord,Jordi de Batlle,Rohit Ail,Enrico Motta,Catherine Bale,Claire Fuller,Anna Mullard,C. P. Subbe,Dawn Griffiths,N. Wreglesworth,Leandro Pecchia,G. Fico,Alessio Antonini +21 more
TL;DR: This study explores the feasibility of using mHealth solutions to monitor survivors of cancer, focusing on their engagement with the monitoring solution and recording clinically relevant subjective and objective measures.
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Janette Greenhalgh,Adrian Bagust,Angela Boland,Kerry Dwan,Sophie Beale,Juliet Hockenhull,C Proudlove,Yenal Dundar,Marty Richardson,Rumona Dickson,Anna Mullard,Ernie Marshall +11 more
TL;DR: The clinical effectiveness and cost-effectiveness of erlotinib and gefitinib compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy is appraised.